Finally, Mizuho restated a "buy" rating and issued a $19.00 price target (up from $18.00) on shares of Endo International PLC in a research report on Thursday, May 25th.
Edmond De Rothschild Holding S.a. says it lowered its ownership in Endo International plc - Ordina shares by 279,600 shares in the quarter ending 06/30/2017. Canaccord Genuity set a $12.00 price objective on Endo International PLC and gave the stock a "hold" rating in a research note on Thursday, June 8th.
Equity analyst Cantor Fitzgerald started covering the stock with an initial rating of "Hold". On June 9, 2017 the stock rating was changed to a "Hold" by Stifel Nicolaus which is down from the previous "Buy" rating. The company has an average rating of "Hold" and a consensus target price of $14.86. The stock exchanged hands 13.4 Million shares versus average trading capacity of 6.04 Million shares, yielding a market cap of $1.78 Billion. The company had a trading volume of 1,057,146 shares.
Over the past 50 days, Endo International plc stock's -46.64% off of the high and -3.33% removed from the low.
Endo Int'l Plc (NASDAQ:ENDP) has average revenue estimates of $792.85 Million, compared to low analyst estimates of $742.1 Million and high estimates of $821.8 Million for the current quarter.
Several blemishing value in the stock market possibly will oblige dedication of a person and lot of hard work. Previously Endo Int'l Plc (NASDAQ:ENDP) reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.2 with surprise factor of 27.4%.
WARNING: "Endo International PLC (NASDAQ:ENDP) PT Set at $13.00 by Deutsche Bank AG" was posted by Markets Daily and is the sole property of of Markets Daily. The company had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. Analysts expect next quarter's EPS will be $0.72 with next year's EPS anticipated to be $3.06. The company's revenue was down 4.9% compared to the same quarter a year ago. Meeder Asset Management Inc. boosted its position in shares of Endo International PLC by 1.4% in the second quarter.
TRADEMARK VIOLATION NOTICE: This article was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and worldwide trademark and copyright law. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/fy2020-eps-estimates-for-endo-international-plc-nasdaqendp-lifted-by-analyst/1435927.html.
In other Endo International PLC news, COO Terrance J. Coughlin acquired 20,000 shares of the company's stock in a transaction dated Thursday, August 10th. The shares were bought at an average cost of $7.70 per share, for a total transaction of $154,000.00. The short sellers will then buy the stock back at a much lower price and replace the borrowed shares, pocketing the difference.
Hedge funds have recently added to or reduced their stakes in the company. Its position was valued at $105,788,000 an increase of $63,107,000 as of quarter end. Nationwide Fund Advisors now owns 360,787 shares of the company's stock worth $4,030,000 after buying an additional 16,913 shares during the period. OppenheimerFunds Inc. increased its position in Endo International PLC by 182.9% in the first quarter. The value of the company's investment in Endo International plc - Ordina went from $4,332,000 to $4,432,000 a change of $100,000 quarter over quarter. Hartford Investment Management Co. acquired a new position in Endo International PLC during the first quarter worth approximately $1,363,000. Finally, TIAA CREF Investment Management LLC boosted its stake in shares of Endo International PLC by 1.6% in the second quarter. Parametric Portfolio Associates LLC now owns 398,099 shares of the company's stock worth $4,447,000 after buying an additional 62,822 shares during the last quarter.
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services.